跳至主要内容
临床试验/NCT00971776
NCT00971776终止3 期

Voyager I: Patient Discharge Using the AB5000 Portable Driver System

Abiomed Inc.0 个研究点目标入组 9 人开始时间: 2008年6月1日最近更新:
适应症

试验速览

阶段
3 期
状态
终止
发起方
Abiomed Inc.
入组人数
9
主要终点
Adverse events, Quality of life assessment, NIH Stroke Scale Assessments, and patient outcome after readmission

研究概览

简要总结

The AB Portable Driver System will allow patients supported with the Circulatory Support System to be discharged home when their medical condition improves to an ambulating status and will continue to receive the assistance of the AB 5000 ventricle for their heart recovery.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The subject is an AB5000 Circulatory Support System patient (in accordance FDA-approved indications for use) who is suffering acute cardiac dysfunction and is potentially recoverable;
  • The subject is male or female, age 18 years or older;
  • The subject is able to ambulate unassisted;
  • The subject is on stable oral anticoagulation over 7 days (INR 2-4) with no active bleeding;
  • The subject is willing and able to read, understand and sign the study specific informed consent form;
  • The subject agrees to comply with study protocol requirements, including all follow-up visits and completion of Qol and NIH stroke scale assessments.

排除标准

  • The subject, pre-device implant, is qualified as a transplant candidate.
  • There is an absence of a trained companion.
  • There is an absence of a psycho-social support.
  • The subject has an inadequate home environment, such as poor access which may hinder movements.
  • The subject has experienced hypotension in last 24 hours based on two consecutive readings spaced by 8 hours with systolic blood pressures < 90 mmHg.
  • The subject requires respiratory assistance.
  • The subject has an active infection (positive blood culture and/or body T ≥ 38 degrees C, and/or WBC ≥ 12K/µL).
  • The subject requires tube feeding.
  • The subject has any other medical condition requiring hospitalization.

结局指标

主要结局

Adverse events, Quality of life assessment, NIH Stroke Scale Assessments, and patient outcome after readmission

时间窗: Pre-discharge, 30 days post-discharge, 90 days or re-admission

次要结局

未报告次要终点

研究者

发起方
Abiomed Inc.
申办方类型
Industry
责任方
Sponsor

相似试验